GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Summit Therapeutics
Summit Therapeutics is a biotechnology company focused on developing new antibiotics to combat drug-resistant infections. Its stock price reflects investors' faith in the breakthrough potential of its drugs in a field where innovation is vital.
Share prices of companies in the market segment - Pharma infections
Summit Therapeutics is a biotech company focused on developing new antibiotics. We classify it as an infection control pharmaceutical. The chart below illustrates the overall dynamics of this sector, where scientific breakthroughs coexist with high risks.
Broad Market Index - GURU.Markets
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics for the treatment of resistant bacterial infections. Its market capitalization earns it a spot in the GURU.Markets index. The chart below shows the overall market performance. Compare this biotech player's stock to the overall trend.
Change in the price of a company, segment, and market as a whole per day
SMMT - Daily change in the company's share price Summit Therapeutics
The daily price change for Summit Therapeutics, a company developing anti-infection drugs, is a measure of its high volatility and reaction to clinical trial news. While the chart of these fluctuations is unspectacular, it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma infections
Summit Therapeutics Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparing it to SMMT's performance, which depends on the clinical trial results of its drugs, helps assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Summit Therapeutics is a biopharmaceutical company developing new antibiotics to combat resistant infections. This segment of biotech is highly volatile. The chart below reflects average fluctuations in this industry, providing context for assessing the risks and potential of Summit shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Summit Therapeutics
Summit Therapeutics is a biotech company specializing in infectious diseases. Its shares are driven by news about the development of new antibiotics. This dynamic, specific to the pharmaceutical industry, creates fluctuations that contribute to overall volatility.
Annual dynamics of market capitalization of the market segment - Pharma infections
Summit Therapeutics Inc. is a biotechnology company focused on developing innovative antibiotics to combat resistant infections. Its success depends on clinical trial results and regulatory approval. The timeline reflects the high risks and potential for breakthroughs in this critically important area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics for the treatment of infectious diseases. Its growth, like that of other biotech companies, is not driven by economics but by clinical trial results and regulatory approvals. This is a high-risk bet on a scientific breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Summit Therapeutics
Summit Therapeutics, a biopharmaceutical company, is a speculative company. Monthly fluctuations on the chart do not reflect business cycles, but rather are a direct reaction from investors to news about the progress of clinical trials of its innovative drugs, the results of which will ultimately determine the company's future.
Monthly dynamics of market capitalization of the market segment - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing a new class of antibiotics to combat superbugs. Its sector dynamics, shown in the chart, reflect the high risk of clinical trials. Against this backdrop, it's possible to assess how the urgent need for new antibiotics and the potential of its lead drug influence investor valuations of the company.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Summit Therapeutics is a biopharmaceutical company focused on developing next-generation antibiotics. Its shares, like many biotech companies, are awaiting clinical trial data. The chart below shows how the company's performance has been out of sync with the broader market, driven by specific news rather than macroeconomic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Summit Therapeutics
The short-term volatility of Summit Therapeutics, a clinical-stage biotech, is entirely dependent on news. Trial data, FDA decisions, or funding announcements can trigger extreme stock movements, reflecting the binary nature of risk: either success or failure.
Weekly dynamics of market capitalization of the market segment - Pharma infections
Summit Therapeutics and the entire early-stage biotech sector are a zone of extreme volatility driven by overall investor sentiment. The success of one company can ignite interest in the entire niche. The chart shows how the company's shares react to this general "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Summit Therapeutics is a clinical-stage biotech. Its shares are essentially a bet on the success of one or two drugs. The chart clearly demonstrates this "binary" risk: its dynamics are determined by trial news, not the market.
Market capitalization of the company, segment and market as a whole
SMMT - Market capitalization of the company Summit Therapeutics
Summit Therapeutics' market capitalization chart is a visual representation of the high stakes of biotech. It reflects investor hopes for its breakthrough lung cancer drug ivonescimab, particularly in the Chinese market. Its highly volatile performance is a classic biotech story, where a company's value can soar or collapse on clinical trial news.
SMMT - Share of the company's market capitalization Summit Therapeutics within the market segment - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics for the treatment of infectious diseases. Its market capitalization reflects its high potential for success if its drugs are successful. The chart is a story of high hopes and high risks.
Market capitalization of the market segment - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics and cancer drugs. The chart below shows the sector's market capitalization. Its dynamics reflect both the urgent need for new treatments and the high risks of clinical trials that Summit is undertaking.
Market capitalization of all companies included in a broad market index - GURU.Markets
Fighting infectious diseases is a constant challenge for biotech companies driving value. Summit Therapeutics is focused on developing new antibiotics to combat superbugs. Its valuation represents a risky bet on a scientific breakthrough in a field where many have failed.
Book value capitalization of the company, segment and market as a whole
SMMT - Book value capitalization of the company Summit Therapeutics
Summit Therapeutics' book value is the material foundation for fighting infections. The chart reflects the capital raised for costly clinical research and the development of new antibiotics. These are financial assets that the company strives to transform into real, life-saving treatments.
SMMT - Share of the company's book capitalization Summit Therapeutics within the market segment - Pharma infections
Summit Therapeutics focuses on developing drugs for infectious diseases. Its share of the sector's assets is determined by its R&D laboratories. The chart shows that at this stage, the company is investing in building a scientific and intellectual base rather than in large-scale production.
Market segment balance sheet capitalization - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing drugs for infectious diseases. Their value is created in labs, not factories. A book value chart shows that their physical asset base is relatively modest, as their primary asset is intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Summit Therapeutics' assets include primarily its intellectual property, but also its laboratories for developing new antibiotics. The chart below shows how the company is building its material and scientific foundation to combat drug-resistant infections.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Summit Therapeutics
Summit Therapeutics' assets are laboratories. Its market valuation is a bet on the success of its new infection drug. The chart visualizes how the odds of this breakthrough have changed in the eyes of investors.
Market to book capitalization ratio in a market segment - Pharma infections
Summit Therapeutics is a clinical-stage biotech developing new antibiotics. Its valuation is based almost entirely on the expected success of future drugs. The chart shows a huge valuation over its current assets, reflecting the high risk and potential reward.
Market to book capitalization ratio for the market as a whole
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing new antibiotics and oncology drugs. Its current valuation, compared to the average on this chart, is unrelated to its assets. It's a pure bet by investors on the scientific success of its developments, where the potential reward in case of success is enormous, as is the risk of failure.
Debts of the company, segment and market as a whole
SMMT - Company debts Summit Therapeutics
Summit Therapeutics, a clinical-stage biotech, relies entirely on external funding for its research. This chart shows how the company raises capital (often through equity issuance or convertible debt) to finance expensive and lengthy trials of its experimental drugs, hoping for a future breakthrough.
Market segment debts - Pharma infections
Summit Therapeutics is a clinical-stage biotech focused on developing new antibiotics to combat resistant infections. This is an area of high medical need, but also carries significant scientific and financial risks. This chart shows the financial position of a company going all-in on a scientific breakthrough.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Summit Therapeutics
Summit Therapeutics is a clinical-stage biotech company focused on developing new antibiotics and oncology drugs. This chart shows its debt load. Without commercial products, debt is a means of survival to fund R&D. Failure of key trials could lead to inability to service the debt.
Market segment debt to market segment book capitalization - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat resistant infections. This is a critically important but complex area with high risks in R&D. The chart shows how aggressively the biotech sector uses debt to fund research, and how Summit compares to this.
Debt to book value of all companies in the market
Summit Therapeutics develops drugs to treat infections. The biotech financing model is unique. This chart shows the average debt load of the entire economy. It allows us to assess how Summit's financial structure, dependent on R&D success, differs from that of more predictable sectors.
P/E of the company, segment and market as a whole
P/E - Summit Therapeutics
Summit Therapeutics is a biotech company focused on developing new antibiotics to combat drug-resistant infections and oncology treatments. This chart reflects high, yet risky, investor expectations. Its dynamics are a bet on the success of clinical trials and the ability to solve one of the most pressing healthcare problems.
P/E of the market segment - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics to combat infections caused by drug-resistant bacteria, one of the most pressing challenges in modern healthcare. This chart shows the average valuation for the pharmaceutical sector, reflecting investor expectations for the fight against superbugs.
P/E of the market as a whole
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics and cancer drugs. This chart reflects the overall sentiment in biotech, but for SMMT, as a clinical-stage company, investor confidence in its scientific approach is crucial. Its valuation is driven by research data, not the market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Summit Therapeutics
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat drug-resistant infections. This chart reflects investor confidence in its lead drug. The indicator's performance is a highly speculative estimate of the company's chances of successfully completing clinical trials and securing regulatory approval, which could generate significant profits.
%20P%2FE%20Summit%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Summit-Therapeutics&v=1772574778340 "Chart of the company's future (projected) P/E Summit Therapeutics")
Future (projected) P/E of the market segment - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to treat infections caused by resistant bacteria. This chart shows the company's estimated future revenue in the context of the biotech sector. It demonstrates how much investors believe in its ability to solve one of the most pressing healthcare problems.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772574778359 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat infectious diseases. Given the overall market expectations shown by this chart, Summit's business depends on scientific breakthroughs. The success of their clinical trials and the potential of their drugs to address antibiotic resistance are what drive their value.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772574778430 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Summit Therapeutics
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics to combat drug-resistant infections, an area with a huge unmet medical need. This chart reflects the company's financial performance during the challenging journey of clinical trials and the search for breakthrough solutions.
Profit of companies in the market segment - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics. This chart shows profitability in the pharmaceutical sector. For the SMMT, which operates in the complex field of infection control, this indicates the market's willingness to invest in new antibiotics, despite the economic challenges of commercializing them.
Overall market profit
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics to combat superbugs. This is an area of significant unmet medical need. The company's success depends solely on clinical trial results. This graph does not reflect the specific risks or the enormous potential of biotech breakthroughs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Summit Therapeutics
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics to combat superbugs. The revenue projections presented here are highly speculative and reflect expectations based on clinical trial results and the potential commercial success of its lead drug, ivontraline.
%20profit%20of%20the%20company%20Summit%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Summit-Therapeutics&v=1772574778627 "Graph of future (projected) profit of the company Summit Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma infections
Summit Therapeutics is a biotech company focused on developing new antibiotics to combat drug-resistant superbugs. The revenue forecast for this segment reflects both the urgent medical need and the high risks. This chart shows analysts' confidence in the commercial success of new approaches to treating infectious diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772574778645 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics and oncology drugs. Its future depends on the success of clinical trials. The market-wide profit projections reflected here impact the availability of venture capital, which is vital for funding such research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772574778687 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Summit Therapeutics
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat infectious diseases. This chart reflects a high, yet speculative, valuation. With modest current revenue, investors are betting on a potential breakthrough in the treatment of drug-resistant bacteria, which could generate billions in revenue.
P/S market segment - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics to combat infections caused by drug-resistant bacteria. This chart shows the industry average price-to-sales ratio. It reflects investor expectations for clinical trials and the company's potential to solve one of the most pressing healthcare challenges.
P/S of the market as a whole
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics to treat serious infectious diseases resistant to existing drugs. Its success depends on the results of clinical trials. This chart provides a general revenue estimate for analyzing how the market perceives the potential for breakthroughs in the fight against superbugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Summit Therapeutics
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat drug-resistant infections. This chart shows how investors estimate the company's future, yet unrealized, revenue. It reflects expectations for the success of its drugs in combating the global threat of superbugs.
%20P%2FS%20Summit%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Summit-Therapeutics&v=1772574778982 "The graph of the company's future (projected) P/S Summit Therapeutics")
Future (projected) P/S of the market segment - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat drug-resistant infections, an area with a high unmet medical need. This chart reflects investors' confidence in its scientific approach and the potential of its drugs to become a new standard of care.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772574779060 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing new treatments for infectious diseases and cancer. Their value depends on the success of trials. This market optimism curve is critical for Summit. Access to capital to fund expensive research is only possible when investors are willing to take risks in anticipation of a breakthrough.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772574779139 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Summit Therapeutics
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics for the treatment of serious infectious diseases. This chart shows the early stage of clinical development. Currently, the company's revenue is minimal, as its lead drug is in clinical trials. Future growth will depend on the success of these trials and regulatory approval.
Sales of companies in the market segment - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat drug-resistant infections, one of the most pressing global health challenges. Currently in clinical development, their future revenue will depend on the success of their lead drug, ivoparaub.
Overall market sales
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics to treat infections caused by drug-resistant bacteria. This problem is one of the most serious threats to global health. This total revenue chart includes the healthcare sector, where the SMMT aims to address a critical medical need.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Summit Therapeutics
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics for the treatment of serious infectious diseases. This graph reflects future revenue expectations, which are almost entirely dependent on the success of clinical trials and the subsequent approval and commercial launch of its key drug, ivoparamcin.
%20sales%20of%20the%20company%20Summit%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Summit-Therapeutics&v=1772574779439 "Schedule of future (projected) sales of the company Summit Therapeutics")
Future (projected) sales of companies in the market segment - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics to combat drug-resistant infections. This chart shows forecasts for the entire antibacterial drug market. It reflects the growing global problem of antibiotic resistance and the potential for companies offering new solutions.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772574779572 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat infectious diseases. While the need for such drugs is critical, the economic projections in this chart are important. They impact the company's ability to attract the significant investment required to conduct lengthy and costly clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772574779749 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Summit Therapeutics
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics and cancer treatments. This chart shows its financial performance at the clinical development stage. Its profitability is negative due to high research costs and the lack of commercial products. Success depends on the approval and launch of its drugs.
Market segment marginality - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to treat infections resistant to existing drugs. Profitability in this critical but complex field depends on the success of clinical trials. This chart reflects the financial costs of research. Investors evaluate it in the context of a potential breakthrough in the fight against superbugs.
Market marginality as a whole
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat resistant infections. This is an area of high unmet medical need. The company's success depends on clinical data and regulatory support, not on the general economic trends reflected in this chart.
Employees in the company, segment and market as a whole
Number of employees in the company Summit Therapeutics
Summit Therapeutics is a biotech company focused on one of the most pressing healthcare challenges: antibiotic resistance. This graphic shows a small but highly specialized team of scientists developing a new generation of antibiotics capable of defeating superbugs. Their work is crucial for the future of medicine.
Share of the company's employees Summit Therapeutics within the market segment - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics to combat drug-resistant infectious diseases. This chart illustrates its scientific focus. It reflects the proportion of microbiologists and infectious disease specialists Summit employs to address one of the most pressing healthcare challenges.
Number of employees in the market segment - Pharma infections
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat drug-resistant superbugs, one of the leading threats to global health. This chart shows the growth of the team of scientists racing against time to create treatments for these evolving infections.
Number of employees in the market as a whole
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat drug-resistant infections. This focus is critical to global health. The economic environment, reflected in this graph through employment, impacts the ability of governments and hospitals to finance the purchase of innovative, but potentially expensive, drugs to address this growing threat.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Summit Therapeutics (SMMT)
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics. This chart reflects the high risk and potential of this field. The high market capitalization per employee (in development) reflects investors' faith in the scientific platform and the potential of its drugs to address the problem of antibiotic resistance.
%20of%20the%20company%20Summit%20Therapeutics%20(SMMT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Summit-Therapeutics-SMMT&v=1772574780690 "Chart of market capitalization per employee (in thousands of dollars) of the company Summit Therapeutics (SMMT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
Summit Therapeutics is a biotech company developing new treatments for infectious diseases. Like many clinical-stage biotechs, its value is derived not from its assets but from the hopes of a future drug. This chart shows the industry average, reflecting that a company's market value is based on its IP, not its large workforce.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772574780731 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat superbugs. In biotech, this metric reflects the potential of its scientific research. A high valuation per employee reflects investors' bet that a small team of scientists can solve one of the most pressing problems in modern medicine.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772574781042 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Summit Therapeutics (SMMT)
Summit Therapeutics is a clinical-stage biotech focused on oncology. This graph is likely negative for them. The company is comprised of scientists and managers who spend investor capital on R&D. Every employee represents an expense necessary to bring a promising drug to approval and future revenue.
%20Chart%20Summit%20Therapeutics%20(SMMT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Summit-Therapeutics-SMMT&v=1772574781116 "Company Profit Per Employee (in thousands of dollars) Chart Summit Therapeutics (SMMT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
Summit Therapeutics is a clinical-stage biotech developing a breakthrough drug (Ivonescimab) for cancer. This chart shows the benchmark for "Pharma Infections" (Biotech). In this sector, the benchmark is *negative*. Companies are burning billions on R&D in hopes of a future blockbuster.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772574781189 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics for the treatment of infectious diseases. This graph, demonstrating the value of human capital, underscores the importance of their mission. A small team of scientists is working to address the global problem of antibiotic resistance, and their success will have enormous value.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772574781244 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Summit Therapeutics (SMMT)
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to combat infectious diseases. This graph will reflect the transition from research to commercialization. Growth in revenue per employee will be a key indicator of the success of its drugs in gaining approval and reaching the market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Summit-Therapeutics-SMMT&v=1772574781427 "Sales chart per company employee Summit Therapeutics (SMMT)")
Sales per employee in the market segment - Pharma infections
Summit Therapeutics is a clinical-stage biotech focused on infectious diseases and oncology. They have a promising drug but don't yet have stable revenue. This chart compares their R&D costs (personnel) with zero revenue, compared to a sector where many companies already have sales.
Sales per employee for the market as a whole
Summit Therapeutics is a clinical-stage biotech company focused on developing next-generation antibiotics and cancer drugs. It's a venture-backed R&D company. This graph will likely show very little or no revenue, as their research team is still working to bring their products to market.
Short shares by company, segment and market as a whole
Shares shorted by company Summit Therapeutics (SMMT)
Summit Therapeutics (SMMT) is a biotech company focused on developing new antibiotics to combat superbugs and oncology drugs. This chart shows bearish bets. High short positions are common in biotech. In SMMT's case, investors may bet against the success of their key drug or fear intense competition and the challenges of bringing new antibiotics to market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Summit-Therapeutics-SMMT&v=1772574781816 "Short Shares Chart for the Company Summit Therapeutics (SMMT)")
Shares shorted by market segment - Pharma infections
Summit Therapeutics (SMMT) is a biopharmaceutical company focused on developing new antibiotics to treat drug-resistant infections. This chart illustrates the general skepticism in the biotech sector. It summarizes bearish bets, reflecting investor concerns about the risks of clinical trials in this complex niche.
Shares shorted by the overall market
Summit Therapeutics (SMMT) is a clinical-stage biotech focused on developing new antibiotics and oncology drugs. This chart measures the overall level of fear. For venture-backed biotechs without revenue, like SMMT, rising market pessimism threatens a capital drought. Investors are afraid to risk money on long-term research during a stormy market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Summit Therapeutics (SMMT)
Summit Therapeutics is a biotech company going all-in on developing new antibiotics against superbugs. It's a high-risk bet. The chart reflects wild speculation: the stock is overheated (above 70) on any positive signal from the FDA or trial data, and oversold (below 30) amid delays or capital dilution.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Summit-Therapeutics-SMMT&v=1772574782207 "RSI 14 indicator chart for the company's stock Summit Therapeutics (SMMT)")
RSI 14 Market Segment - Pharma infections
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics to combat multidrug-resistant infections, as well as oncology drugs (ivonescimab). This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how Summit stands out.
RSI 14 for the overall market
Summit Therapeutics is a biopharmaceutical company focused on developing innovative antibiotics for the treatment of multidrug-resistant infections. This is a very risky but important segment. This market sentiment indicator reflects risk appetite. Venture-backed biotech stocks, like SMMT, soar during periods of euphoria but collapse during panic, when investors flee speculative assets.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SMMT (Summit Therapeutics)
Summit Therapeutics is a biopharmaceutical company focused on developing new antibiotics to treat drug-resistant infections. This chart shows analyst consensus forecasts. Their targets depend almost entirely on clinical trial results and potential regulatory approval of their key drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SMMT-Summit-Therapeutics&v=1772574782305 "A chart showing analyst consensus forecasts for the expected stock price. SMMT (Summit Therapeutics)")
The difference between the consensus estimate and the actual stock price SMMT (Summit Therapeutics)
Summit Therapeutics is a biotech company whose fate depends almost entirely on a single drug: ivonescimab, a potential blockbuster treatment for lung cancer. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the success of clinical trials and the drug's commercial potential.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SMMT-Summit-Therapeutics&v=1772574782370 "A chart showing the difference between the consensus forecast and the actual stock price. SMMT (Summit Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing new antibiotics and oncology drugs. It's a high-risk business. This chart shows analysts' overall expectations for the entire biotech sector. It reflects whether experts believe in the success of the industry's R&D pipelines.
Analysts' consensus forecast for the overall market share price
Summit Therapeutics is a clinical-stage biotech focused on infectious diseases and oncology. It's an R&D company burning cash. The overall market sentiment, visible in this chart, is their access to capital. During downturns (negative expectations), investors are reluctant to fund risky biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Summit Therapeutics
Summit Therapeutics is a clinical-stage biotech betting on a breakthrough drug (ivonescimab) for lung cancer, particularly in the huge Chinese market. This chart is a classic biotech indicator. It doesn't reflect current profits, but rather a purely speculative estimate of clinical trial data and the chances of approval for their potential blockbuster.
AKIMA Market Segment Index - Pharma infections
Summit Therapeutics is a high-risk biotech that has made an all-in bet on a single asset (ivonescimab), an experimental lung cancer drug that (according to reports) could challenge the king of the drug, Keytruda (Merck). This composite metric measures R&D. The chart shows the segment average. This is a benchmark: how does this extreme (all-or-nothing) SMMT bet differentiate it from the average pharma company?
The AKIM Index for the overall market
Summit Therapeutics is a development-stage biotech company focused on developing breakthrough antibiotics to combat superbugs. It's a high-risk bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative scientific story, driven by trial news, stacks up against broader economic trends.
